Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 8:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 107 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: interferon beta-1a Clear all

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: John F. Foley, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Multiple Sclerosis
Interventions: Laquinimod, Placebo, Avonex®; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more

Conditions: Multiple Sclerosis
Interventions: Teriflunomide, Placebo (for Teriflunomide), Interferon-β; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Early Highly Effective Therapies Group, Escalation Therapies Group; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 60 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 15
States / cities: Aurora, Colorado • Minneapolis, Minnesota • Rochester, Minnesota + 11 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Natalizumab, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more

Conditions: Relapsing Remitting Multiple Sclerosis (RRMS)
Interventions: New Formulation of rebif - human interferon beta-1a, Interferon beta -1b; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Covid19
Interventions: IFN beta-1a, Dexamethasone; Drug
Lead sponsor: Faron Pharmaceuticals Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Aurora, Colorado • Boston, Massachusetts • Newton, Massachusetts + 1 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Glatiramer acetate, (Copaxone®), IFN-β-1a, (Avonex®); Drug
Lead sponsor: Neurognostics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: Los Angeles, California • Seattle, Washington • Madison, Wisconsin + 1 more

Conditions: Multiple Sclerosis
Interventions: Interferon beta 1a, oral doxycycline; Drug
Lead sponsor: Louisiana State University Health Sciences Center Shreveport; Other
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Alemtuzumab, Interferon beta-1a; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 581 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 36
States / cities: Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 31 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: alemtuzumab; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: Not listed
Enrollment: 1,314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 69
States / cities: Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 60 more

Conditions: Multiple Sclerosis
Interventions: Interferon beta-1a, Fingolimod, Placebo capsule, Placebo i.m. injection; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2030
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more

Conditions: Multiple Sclerosis
Interventions: Diroximel Fumarate, Alemtuzumab, Fingolimod, Glatiramer acetate, Interferon beta, Natalizumab, Ocrelizumab, Ofatumumab, Ozanimod, Peginterferon beta-1a, Ponesimod, Siponimod; Drug · Biological
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 1,178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 1
States / cities: Eden Prairie, Minnesota

Conditions: Multiple Sclerosis
Interventions: Mycophenolate Mofetil (cellcept); Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Multiple Sclerosis
Interventions: ACTH, Methylprednisolone; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: dimethyl fumarate, Interferon β-1a; Drug
Lead sponsor: Biogen; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts • Charlottesville, Virginia

Conditions: Multiple Sclerosis
Interventions: Avonex and Topamax; Drug
Lead sponsor: Multiple Sclerosis Institute; Other
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Interferon beta-1a, Alemtuzumab 12 mg, Alemtuzumab 24 mg; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 31
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 27 more

Conditions: Multiple Sclerosis
Interventions: Avonex® monotherapy (6.0 MIU administered i.m. each week); Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Multiple Sclerosis
Interventions: Interferon-beta-1a FBS-free/HSA-free; Biological
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Relapsing Multiple Sclerosis
Interventions: BIIB017, naproxen; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 38
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 34 more

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Not listed
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Foxborough, Massachusetts

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: BIIB019 (Daclizumab High Yield Process), Interferon beta-1a Placebo, Interferon beta-1a, Daclizumab High Yield Process Placebo; Biological · Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,841 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 46
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 43 more

Search by objective public record fields.

Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)

Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis

RNF and Betaseron® Tolerability Study

Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19

The Role of Serum Leptin Levels in Multiple Sclerosis Disease Activity While on Interferon Beta 1a (Rebif) Treatment

An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis

Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One

An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis

Pulse ACTH vs. MP for MS

Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis

A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MS

Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis

Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)

Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes

Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis